Emergency care for children with sickle cell disease: a focus on pain and fever.

IF 2.1 4区 医学 Q2 HEMATOLOGY
Rawan Korman, Dunia Hatabah, Claudia R Morris
{"title":"Emergency care for children with sickle cell disease: a focus on pain and fever.","authors":"Rawan Korman, Dunia Hatabah, Claudia R Morris","doi":"10.1080/17474086.2025.2538537","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 100,000 individuals in the United States and millions worldwide, characterized by acute vaso-occlusive pain episodes (VOEs) and other complications that frequently necessitate emergency department (ED) visits.</p><p><strong>Areas covered: </strong>Despite therapeutic advancements, ED care remains a major concern, often cited by patients as the area of healthcare most in need of improvement. National guidelines have been established to ensure ideal emergency SCD care and management, however, these guidelines do not address barriers or facilitators that affect implementation in the complex ED setting. This review examines current diagnostic and management approaches for common SCD complications requiring ED utilization, particularly fever and pain in pediatric patients. It highlights the challenges children with SCD face in emergency care and the existing knowledge gaps. Despite guidelines recommending timely, individualized pain treatment, implementation remains inconsistent, resulting in prolonged suffering and increased hospitalizations.</p><p><strong>Expert opinion: </strong>Future research should focus on enhancing guideline adherence, reducing disparities, and developing targeted therapies. Novel biomarkers could improve early diagnosis, while standardized severity scoring systems may optimize triage and treatment decisions. Advancing biomarker research and investigational therapies beyond traditional supportive care holds promise for improving SCD management and patient outcomes.</p>","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-23"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2538537","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 100,000 individuals in the United States and millions worldwide, characterized by acute vaso-occlusive pain episodes (VOEs) and other complications that frequently necessitate emergency department (ED) visits.

Areas covered: Despite therapeutic advancements, ED care remains a major concern, often cited by patients as the area of healthcare most in need of improvement. National guidelines have been established to ensure ideal emergency SCD care and management, however, these guidelines do not address barriers or facilitators that affect implementation in the complex ED setting. This review examines current diagnostic and management approaches for common SCD complications requiring ED utilization, particularly fever and pain in pediatric patients. It highlights the challenges children with SCD face in emergency care and the existing knowledge gaps. Despite guidelines recommending timely, individualized pain treatment, implementation remains inconsistent, resulting in prolonged suffering and increased hospitalizations.

Expert opinion: Future research should focus on enhancing guideline adherence, reducing disparities, and developing targeted therapies. Novel biomarkers could improve early diagnosis, while standardized severity scoring systems may optimize triage and treatment decisions. Advancing biomarker research and investigational therapies beyond traditional supportive care holds promise for improving SCD management and patient outcomes.

镰状细胞病儿童的紧急护理:关注疼痛和发烧。
简介:镰状细胞病(SCD)是一种遗传性血液疾病,在美国影响约100,000人,在全球影响数百万人,其特征是急性血管闭塞性疼痛发作(VOEs)和其他并发症,经常需要急诊(ED)就诊。涵盖领域:尽管治疗取得了进步,但急诊科护理仍然是一个主要问题,经常被患者引用为最需要改进的医疗保健领域。已经制定了国家指南,以确保理想的紧急急诊科护理和管理,然而,这些指南没有解决在复杂的急诊科环境中影响实施的障碍或促进因素。本综述探讨了目前需要ED治疗的常见SCD并发症的诊断和治疗方法,特别是儿科患者的发热和疼痛。它突出了患有SCD的儿童在紧急护理方面面临的挑战和现有的知识差距。尽管指南建议及时、个性化的疼痛治疗,但实施仍然不一致,导致痛苦延长和住院人数增加。专家意见:未来的研究应侧重于加强指南的遵守,减少差异,并开发靶向治疗。新的生物标志物可以改善早期诊断,而标准化的严重程度评分系统可以优化分诊和治疗决策。推进生物标志物研究和研究性治疗,超越传统的支持治疗,有望改善SCD的管理和患者的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.70
自引率
3.60%
发文量
98
审稿时长
6-12 weeks
期刊介绍: Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信